Incretin-based therapy, including dipeptidyl peptidase–4 (DPP–4) inhibitors and glucagon-like peptide–1 receptor (GLP-1R) agonists, has become a popular treatment for type 2 diabetes. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.